Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Advanced Solid Tumor 6Carcinoma, Hepatocellular 4Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Advanced Solid Tumors 2Advanced Lung Cancer 2Urinary Bladder Neoplasms 1Treatment-naive Advanced Non-small Cell Lung Cancer 1Sarcoma 1Recurrence 1Mouth Neoplasms 1Melanoma 1Lymphoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced Rectal Cancer 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1High-Risk Resectable NSCLC 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Anus Neoplasms 1Anal Canal Carcinoma 1Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy 1

Interventions

toripalimab 1tislelizumab 1sintilimab 1pembrolizumab 1durvalumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × High-Risk Resectable NSCLC × toripalimab × Clear all
NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Completed
27 enrolled
Thoracic

High-Risk Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡